image
Healthcare - Biotechnology - NASDAQ - US
$ 1.1106
-0.0545 %
$ 3.64 M
Market Cap
-0.37
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ARTL stock under the worst case scenario is HIDDEN Compared to the current market price of 1.11 USD, Artelo Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ARTL stock under the base case scenario is HIDDEN Compared to the current market price of 1.11 USD, Artelo Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ARTL stock under the best case scenario is HIDDEN Compared to the current market price of 1.11 USD, Artelo Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ARTL

image
$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.815 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-10.3 M OPERATING INCOME
-38.25%
-10.1 M NET INCOME
-35.58%
-8.01 M OPERATING CASH FLOW
-30.40%
2.96 M INVESTING CASH FLOW
186.01%
0 FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-2.61 M OPERATING INCOME
-46.52%
-1.6 M NET INCOME
26.25%
-1.62 M OPERATING CASH FLOW
25.75%
399 K INVESTING CASH FLOW
-81.86%
-1.25 M FINANCING CASH FLOW
0.00%
Balance Sheet Artelo Biosciences, Inc.
image
Current Assets 18.3 M
Cash & Short-Term Investments 17.5 M
Receivables 0
Other Current Assets 789 K
Non-Current Assets 2.1 M
Long-Term Investments -1.5 M
PP&E 60 K
Other Non-Current Assets 3.54 M
85.85 %3.86 %17.32 %Total Assets$20.4m
Current Liabilities 998 K
Accounts Payable 905 K
Short-Term Debt 40 K
Other Current Liabilities 53 K
Non-Current Liabilities 23 K
Long-Term Debt 23 K
Other Non-Current Liabilities 0
88.64 %3.92 %5.19 %Total Liabilities$1.0m
EFFICIENCY
Earnings Waterfall Artelo Biosciences, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 10.3 M
Operating Income -10.3 M
Other Expenses -204 K
Net Income -10.1 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)000(10m)(10m)204k(10m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-50.89% ROE
-50.89%
-48.35% ROA
-48.35%
-51.75% ROIC
-51.75%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Artelo Biosciences, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)201520152016201620172017201820182019201920202020202120212022202220232023
Net Income -10.1 M
Depreciation & Amortization 2 K
Capital Expenditures 0
Stock-Based Compensation 2.46 M
Change in Working Capital -172 K
Others -406 K
Free Cash Flow -8.01 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Artelo Biosciences, Inc.
image
ARTL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Artelo Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain. globenewswire.com - 1 week ago
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled “Fatty acid binding proteins and their involvement in anxiety and mood disorders,” that underscores the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders. globenewswire.com - 2 weeks ago
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter globenewswire.com - 1 month ago
New Strong Sell Stocks for April 10th ASTS, ASEKY and ARTL have been added to the Zacks Rank #5 (Strong Sell) List on April 10, 2025. zacks.com - 2 months ago
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April 3, 2025 during the 4th ACE Drug Discovery Summit being held at The Insurance Hall, London, UK. globenewswire.com - 2 months ago
New Strong Sell Stocks for March 28th APEMY, ARTL and CIGI have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2025. zacks.com - 2 months ago
New Strong Sell Stocks for March 6th ARTL, KW and KRP have been added to the Zacks Rank #5 (Strong Sell) List on March 6, 2025. zacks.com - 3 months ago
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2024. globenewswire.com - 3 months ago
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® SOLANA BEACH, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). globenewswire.com - 4 months ago
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland SOLANA BEACH, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it will be presenting data on ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), at the International Medical Cannabis Conference (IMCCB-25) held at the University of Bern, Switzerland February 13-14, 2025. globenewswire.com - 4 months ago
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, or dermatologic and neurological conditions, today announced the completed safety review of the first cohort of eight healthy volunteers in the Company's Phase 1 study of ART26.12. globenewswire.com - 5 months ago
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment globenewswire.com - 6 months ago
8. Profile Summary

Artelo Biosciences, Inc. ARTL

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.64 M
Dividend Yield 0.00%
Description Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Contact 505 Lomas Santa Fe, Solana Beach, CA, 92075 https://www.artelobio.com
IPO Date June 21, 2019
Employees 6
Officers Dr. Steven D. Reich M.D. Chief Medical Officer Mr. Jason H. Baybutt Senior Vice President of Finance Dr. Andrew Yates Ph.D. Senior Vice President & Chief Scientific Officer Mr. Gregory D. Gorgas M.B.A. President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary & Director